Immunocore Holdings (IMCR) EBIT (2021 - 2026)

Immunocore Holdings (IMCR) has reported EBIT for 6 consecutive years, with $7.3 million the latest figure, recorded in Q1 2026.

• Quarterly EBIT rose 301.33% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.5 million (up 27.59% YoY) and the FY2025 annual result came in at -$45.4 million, up 35.63% from the prior year.
• EBIT rose to $7.3 million in Q1 2026 per IMCR's latest filing, from -$19.7 million in the prior quarter.
• Over the last five years, EBIT for IMCR reached as high as $7.3 million in Q1 2026 and fell as low as -$26.5 million in Q1 2024.
• A 5-year average of -$13.4 million and a median of -$15.4 million in 2024 frame the typical range for EBIT.
• Annual changes were most pronounced in 2023 — EBIT sank 294.45% — and 2026, when it soared 301.33%.
• Year by year, EBIT stood at -$26.2 million in 2022, then soared by 34.88% to -$17.1 million in 2023, then dropped by 14.07% to -$19.5 million in 2024, then dropped by 1.23% to -$19.7 million in 2025, then surged by 136.97% to $7.3 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered $7.3 million, -$19.7 million, and -$7.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.